Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | PCNA | P12004 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989410 | 0.85 | PCNA (0.61) | ESR1ESR2PCNASLC7A5ACACB | |
| SCHEMBL25596402 | 0.84 | PCNA (0.50) | ESR1ESR2PCNASLC7A5ACACB | |
| SCHEMBL25596306 | 0.83 | OPRK1 (0.42) | ESR1ESR2SLC7A5OPRD1OPRK1 | |
| SCHEMBL25596175 | 0.78 | ESR1 (0.42) | ESR1ESR2OPRD1OPRK1TAAR1 | |
| SCHEMBL163430 | 0.77 | ACACB (0.62) | ACACB | |
| SCHEMBL256801 | 0.77 | ACACB (0.62) | ACACB | |
| SCHEMBL24202232 | 0.76 | ACACB (0.45) | ESR1ESR2PCNASLC7A5ACACB | |
| SCHEMBL14419803 | 0.76 | ACACB (0.49) | ESR1ESR2PCNAACACBKDM4E | |
| SCHEMBL12313515 | 0.76 | ESR1 (0.54) | ESR1ESR2SLC7A5KDM4EF13A1 | |
| SCHEMBL5490272 | 0.76 | ESR1 (0.54) | ESR1ESR2SLC7A5KDM4EF13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | ESR1 4421/4885ESR2 4494/4885PCNA 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.